CNS Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $34.12M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2024 Ended Mar 31, 2024 | May 16, 2024 | During market hours | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 15, 2023 | Before market open | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 14, 2023 | Before market open | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 15, 2023 | Before market open | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 15, 2022 | Before market open | – | – | – |
| Q1 FY2022 Ended Mar 31, 2022 | May 16, 2022 | After market close | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Mar 3, 2022 | Before market open | – | – | – |
| Q2 FY2021 Ended Jun 30, 2021 | Aug 13, 2021 | Before market open | – | – | – |
| Q4 FY2019 Ended Dec 31, 2019 | Mar 12, 2020 | After market close | – | – | – |
Press releases
Announcements CNS Pharmaceuticals filed with the SEC
Investor Relations: JTC Team [email protected]
Regulation FD disclosure · EX-99.1 to Form 8-K
cnspharma.com NASDAQ: CNSP March 2026 Investor Presentation
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE DATED JULY 18, 2025
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
14 * Graphs represent aggregate data from multiple studies Improved GBM Survival in Combination with Bevacizumab
Regulation FD disclosure · EX-99.1 to Form 8-K
14 * Graphs represent aggregate data from multiple studies Improved GBM Survival in Combination with Bevacizumab
Regulation FD disclosure · EX-99.1 to Form 8-K
CNS Pharmaceuticals Announces Reverse Stock
Other events · EX-99.1 to Form 8-K
Berubicin: Next Major Milestone Primary Analysis Planned H1 2025 x Study enrollment complete 10 Patients on treatment and in survival follow - up continue unchanged Meeting with FDA to discuss the program based on the primary analysis Potential approval
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PRESENTATION DATED DECEMBER 11, 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE DATED OCTOBER 23, 2024
Material agreement · Other events · EX-99.1 to Form 8-K
Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE DATED JULY 3, 2024
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
PRESS RELEASE DATED JUNE 26, 2024
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
PRESS RELEASE DATED JUNE 14, 2024
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
CNS Pharmaceuticals Announces Reverse Stock
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
INVESTOR PRESENTATION April 2024 www.CNSPharma.com NASDAQ: CNSP
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE DATED DECEMBER 18, 2023
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE DATED AUGUST 14, 2023
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE DATED MAY 15, 2023
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE DATED MAY 8, 2023
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Appoints Faith L. Charles, JD
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE DATED NOVEMBER 30, 2022
Material agreement · Other events · EX-99.1 to Form 8-K
HOUSTON, TX (November 28, 2022) – CNS
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
PORTIONS OF PROSPECTUS SUMMARY SECTION OF CNS PHARMACEUTICALS, INC.'S REGISTRATION STATEMENT ON FORM S-1
Other events · EX-99.1 to Form 8-K
CNS Pharmaceuticals Reports Second Quarter 2022
Results of operations · EX-99.1 to Form 8-K
CNS Pharmaceuticals Reports First Quarter 2022
Results of operations · EX-99.1 to Form 8-K
CNS Pharmaceuticals Reports Full Year 2021 Financial
Results of operations · EX-99.1 to Form 8-K
CNS phar m ac e u t ical s 3 Corporate Overview
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE DATED JANUARY 5, 2022
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
INVESTOR PRESENTATION - DECEMBER 2021
Regulation FD disclosure · EX-99.1 to Form 8-K